CHARLOTTE, NC — Bright Path Pharmaceuticals, LLC (privately held), today announced that Luther H. Hodges Jr. will join the Board of Directors. Mr. Hodges is an active life science investor, having invested in and served on the Board of numerous bio-pharmaceutical companies. He is the former Chairman of the Board of North Carolina National Bank (currently Bank of America), Chairman of the Board of Trustees of The College of Santa Fe, former Chairman and Chief Executive Officer of Washington Bancorporation, Undersecretary of the U.S. Department of Commerce, Deputy Secretary of Commerce; and has held numerous Faculty positions at The University of North Carolina at Chapel Hill, Duke University, and the University of New Mexico.
Mr. Quinones stated, “The company is pleased to have Mr. Hodges join the Board and are excited about the knowledge, wisdom and experience that he will contribute to the BPP.” Mr. Allen stated, “I have known Mr. Hodges for many years as a champion of economic development for innovation. He and his family are responsible for many of the most enduring institutions in North Carolina including Bank of America, Research Triangle Park and the NC Council for Economic Development. We are thrilled and fortunate to have him on board.”
About Bright Path Pharmaceuticals, LLC
Bright Path Pharmaceuticals, LLC is a developmental stage bio-pharmaceutical manufacturing company, dedicated to developing best-in-class continuous-flow manufacturing for the pharmaceutical sector. For more information, please visit www.brightpathrx.com.
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Bright Path Pharmaceuticals’ plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, and development activities, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Bright Path Pharmaceuticals’ actual results to be materially different than those expressed in or implied by Bright Path Pharmaceuticals’ forward-looking statements. For Bright Path Pharmaceuticals, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success and design of manufacturing facilities; and Bright Path Pharmaceuticals’ need for and ability to obtain additional financing. Bright Path Pharmaceuticals undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.